Mighty Therapeutics Develops POLG Disease Model for Research
United States, September 16, 2026 Mighty Therapeutics has announced a partnership with the POLG Foundation to develop a novel...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
United States, September 16, 2026 Mighty Therapeutics has announced a partnership with the POLG Foundation to develop a novel...
Boston, Massachusetts, U.S., September 16, 2026 Applied Photonix has announced the launch of ViroZap®, which the company describes as...
Caesarea, Israel, September 15, 2026 Nitinotes has announced the completion of the first EASEâ„¢ clinical trial procedures at Fondazione...
